• A Systematic Review of Value Criteria for Next-Generation Sequencing/Comprehensive Genomic Profiling to Inform Value Framework Development

    May 1, 2024, 00:00

  • Is the Comparator in Your Diagnostic Cost-Effectiveness Model “Standard of Care”? Recommendations from Literature Reviews and Expert Interviews on How to Identify and Operationalize It

    May 1, 2024, 00:00

  • It Is Time to Reconsider the 3% Discount Rate [Editor's Choice]

    May 1, 2024, 00:00

  • Meaningful Change Thresholds and Fatigue Severity Points on Patient-Reported Outcomes by the Fatigue Symptoms and Impacts Questionnaire in Patients With Relapsing Multiple Sclerosis

    May 1, 2024, 00:00

  • Psychometric Evaluation of the Diary for Irritable Bowel Syndrome Symptoms-Constipation in a Prospective Observational Study

    May 1, 2024, 00:00

  • Acceptability of Using Real-World Data to Estimate Relative Treatment Effects in Health Technology Assessments: Barriers and Future Steps [Editor's Choice]

    May 1, 2024, 00:00

  • Economic Evaluations of Establishing Opioid Overdose Prevention Centers in 12 North American Cities: A Systematic Review

    May 1, 2024, 00:00

  • Valuation of EQ-5D-5L in the Kingdom of Saudi Arabia: A National Representative Study [Editor's Choice]

    May 1, 2024, 00:00

  • Development and Valuation of a Preference-Weighted Measure in Age-Related Macular Degeneration From the Vision Impairment in Low Luminance Questionnaire: A MACUSTAR Report

    May 1, 2024, 00:00

  • Mapping Health Technology Assessment Agency Approaches for Biosimilar Value Assessment: An ISPOR Special Interest Group Report [Editor's Choice]

    May 1, 2024, 00:00

  • Table of Contents

    May 1, 2024, 00:00

  • EQ-5D-5L Population Norms and Quality-Adjusted Life Expectancy by Sociodemographic Characteristics and Modifiable Risk Factors for Adults in Queensland, Australia

    May 1, 2024, 00:00

  • Public Acceptance of Measures to Control Infectious Diseases Under Different Scenarios of Severity and Transmissibility [Editor's Choice]

    May 1, 2024, 00:00

  • Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies

    May 1, 2024, 00:00

  • Toward the Implementation of a Value Framework for Diagnostic Technologies: Operationalization, Piloting, and Validation in Latin America

    May 1, 2024, 00:00

  • Editorial Board

    Apr 1, 2024, 08:56

  • Cost of Illness of Head and Neck Cancer in Sweden

    Apr 1, 2024, 00:00

  • Evaluating Policies of Expanding Versus Restricting First-Line Treatment Choices: A Cost-Effectiveness Analysis Framework [Editor's Choice]

    Apr 1, 2024, 00:00

  • Evaluating Recall Periods for Patient-Reported Outcome Measures: A Systematic Review of Quantitative Methods

    Apr 1, 2024, 00:00

  • Validation of China Health-Related Outcomes Measures-Cardiovascular Disease

    Apr 1, 2024, 00:00

  • The Cost of Atrial Fibrillation: A Systematic Review

    Apr 1, 2024, 00:00

  • Table of Contents

    Apr 1, 2024, 00:00

  • The PICOTS-ComTeC Framework for Defining Digital Health Interventions: An ISPOR Special Interest Group Report

    Apr 1, 2024, 00:00

  • Exploring the Comparability Between EQ-5D and the EQ Health and Wellbeing in the General Australian Population

    Apr 1, 2024, 00:00

  • The Determination of Diabetes Utilities, Costs, and Effects Model: A Cost-Utility Tool Using Patient-Level Microsimulation to Evaluate Sensor-Based Glucose Monitoring Systems in Type 1 and Type 2 Diabetes: Comparative Validation

    Apr 1, 2024, 00:00

  • Economic Evaluation of an Enhanced Post-Discharge Home-Based Care Program for Stroke Survivors

    Apr 1, 2024, 00:00

  • A Comparison of Items and Constructs of Standardized Health-Related Quality of Life and Mental Well-Being Measures

    Apr 1, 2024, 00:00

  • Cost and Utility Estimates per Modified Rankin Scale Score up to 2 Years Post Stroke: Data to Inform Economic Evaluations From a Societal Perspective

    Apr 1, 2024, 00:00

  • Benefit-Harm Analysis for Informed Decision Making on Participating in Colorectal Cancer Screening: A Modeling Study

    Apr 1, 2024, 00:00

  • Discrete Event Simulation to Incorporate Infusion Wait-Time When Assessing Cost-Effectiveness of a Chimeric-Antigen Receptor T Cell Therapy

    Apr 1, 2024, 00:00

  • A Review of Meaningful Change Thresholds for EORTC QLQ-C30 and FACT-G Within Oncology [Editor's Choice]

    Apr 1, 2024, 00:00

  • Estimating a Minimal Important Difference for the EQ-5D-5L Utility Index in Dialysis Patients [Editor's Choice]

    Apr 1, 2024, 00:00

  • Partial Orphan Cancer Drugs: US Food and Drug Administration Approval, Clinical Benefit, Trials, Epidemiology, Price, Beneficiaries, and Spending [Editor's Choice]

    Apr 1, 2024, 00:00

  • Opportunities and Challenges for Decentralized Clinical Trial Approaches: European Health Technology Assessment Perspective

    Mar 1, 2024, 00:00

  • Work Productivity Among Younger Breast Cancer Survivors: The Impact of Behavioral Interventions for Depression

    Mar 1, 2024, 00:00

  • Financial Characteristics of Outcomes-Based Agreements: What Do Canadian Public Payers and Pharmaceutical Manufacturers Prefer?

    Mar 1, 2024, 00:00

  • Identifying the Optimum Strategy for Identifying Adults and Children With Celiac Disease: A Cost-Effectiveness and Value of Information Analysis

    Mar 1, 2024, 00:00

  • Are Manufacturing Patents to Blame for Biosimilar Market Launch Delays?

    Mar 1, 2024, 00:00

  • Scoring the Value Assessment Framework for China: A Factorial Survey

    Mar 1, 2024, 00:00

  • Table of Contents

    Mar 1, 2024, 00:00

  • Patient Welfare Implications of Indication-Specific Value-Based Pricing of Multi-Indication Drugs [Editor's Choice]

    Mar 1, 2024, 00:00

  • Unanchored Population-Adjusted Indirect Comparison Methods for Time-to-Event Outcomes Using Inverse Odds Weighting, Regression Adjustment, and Doubly Robust Methods With Either Individual Patient or Aggregate Data [Editor's Choice]

    Mar 1, 2024, 00:00

  • Quantifying the Value of Reduced Health Disparities: Low-Dose Computed Tomography Lung Cancer Screening of High-Risk Individuals Within the United States

    Mar 1, 2024, 00:00

  • Perils of Randomized Controlled Trial Survival Extrapolation Assuming Treatment Effect Waning: Why the Distinction Between Marginal and Conditional Estimates Matters [Editor's Choice]

    Mar 1, 2024, 00:00

  • Modeling Thyroid Cancer Epidemiology in the United States Using Papillary Thyroid Carcinoma Microsimulation Model

    Mar 1, 2024, 00:00

  • Logical Inconsistencies in the Health Years in Total and Equal Value of Life-Years Gained [Editor's Choice]

    Mar 1, 2024, 00:00

  • Drug Pricing, Patient Welfare, and Cost-Effectiveness Analysis

    Mar 1, 2024, 00:00

  • Using the Online Elicitation of Personal Utility Functions Approach to Derive a Patient-Based 5-Level Version of EQ-5D Value Set: A Study in 122 Patients With Rheumatic Diseases From Germany

    Mar 1, 2024, 00:00

  • Editorial Board

    Feb 26, 2024, 08:32

  • Table of Contents

    Feb 1, 2024, 00:00

  • Cost-Effectiveness of Oral Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in the United States

    Feb 1, 2024, 00:00

  • Cost-Effectiveness Analysis of Trastuzumab Deruxtecan Versus Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 Positive Metastatic Breast Cancer in the United States

    Feb 1, 2024, 00:00

  • Patient Preferences in Pulmonary Arterial Hypertension, a Latent Class Analysis to Identify Preference Heterogeneity

    Feb 1, 2024, 00:00

  • Establishing Meaningful Change Thresholds in Patient-Reported Outcomes Among Patients With Anaplastic Lymphoma Kinase-Positive Non–Small Cell Lung Cancer in ALTA-1L Trial

    Feb 1, 2024, 00:00

  • Author Reply

    Feb 1, 2024, 00:00

  • Applying Trial-Derived Treatment Effects to Real-World Populations: Generalizing Cost-Effectiveness Estimates When Modeling Complex Hazards [Editor's Choice]

    Feb 1, 2024, 00:00

  • Emulating Trials and Quantifying Bias: The Convergence of Health Technology Assessment Agency Real-World Evidence Guidance

    Feb 1, 2024, 00:00

  • Health-Related Quality of Life of People Who Inject Drugs: The Enhancing Treatment of Hepatitis C in Opioid Substitution Settings Engage Study

    Feb 1, 2024, 00:00

  • Systematic Review of Outcomes for Assessment of Medication Adherence Enhancing Interventions: An ISPOR Special Interest Group Report

    Feb 1, 2024, 00:00

  • How Well Does the EQ-5D-Y-5L Describe Children With Intellectual Disability?: “There’s a Lot More to My Child Than That She Can’t Wash or Dress Herself.”

    Feb 1, 2024, 00:00

  • Microsimulation Models on Mental Health: A Critical Review of the Literature [Editor's Choice]

    Feb 1, 2024, 00:00

  • Influence of Self-Reported Health Impairments on German EQ-5D-5L Values

    Feb 1, 2024, 00:00

  • The Health Inequality Impact of a New Cancer Therapy Given Treatment and Disease Characteristics

    Feb 1, 2024, 00:00

  • Economic Burden and Service Utilization of Children With Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis

    Feb 1, 2024, 00:00

  • Patient-Reported Outcome-Based Performance Measures in Alternative Payment Models: Current Use, Implementation Barriers, and Principles to Succeed [Editor's Choice]

    Feb 1, 2024, 00:00

  • Editorial Board

    Jan 23, 2024, 09:13

  • Editorial Board

    Jan 9, 2024, 12:13

  • Assessing the Content Validity of Preference-Based Measures in Cancer

    Jan 1, 2024, 00:00

  • Appropriate Categorization of Inequality to Inform Policy Decisions: Estimating Distribution of Lifetime Health Using Alternative Approaches to Socioeconomic Stratification [Editor's Choice]

    Jan 1, 2024, 00:00

  • This Dead or That Dead: Framing Effects in the Evaluation of Health States

    Jan 1, 2024, 00:00

  • A Scoping Review and Taxonomy of Epidemiological-Macroeconomic Models of COVID-19

    Jan 1, 2024, 00:00

  • Two Methods, One Story? Comparing Results of a Choice Experiment and Multidimensional Thresholding From a Clinician Preference Study in Aneurysmal Subarachnoid Hemorrhage [Editor's Choice]

    Jan 1, 2024, 00:00

  • Remembering Victor R. Fuchs, the “Dean” of Health Economics

    Jan 1, 2024, 00:00

  • Evaluation of Flexible Parametric Relative Survival Approaches for Enforcing Long-Term Constraints When Extrapolating All-Cause Survival [Editor's Choice]

    Jan 1, 2024, 00:00

  • Central Venous Access Devices for the Delivery of Systemic Anticancer Therapy: An Economic Evaluation

    Jan 1, 2024, 00:00

  • Multicriteria Decision Analysis and Value Assessment Frameworks: Where Do We Stand? What Next? [Editor's Choice]

    Jan 1, 2024, 00:00

  • Analyzing Pragmatic Trials to Inform Cost-Effectiveness Analyses

    Jan 1, 2024, 00:00

  • Multistakeholder Perceptions of Additional Value Elements for United States Value Assessment of Health Interventions [Editor's Choice]

    Jan 1, 2024, 00:00

  • Negative Drug Pricing in the Context of Cost-Effectiveness Analysis: A Consistency Examination

    Jan 1, 2024, 00:00

  • Testing 2 Alternative Time Trade-Off Methods for Valuation of Children’s Health States

    Jan 1, 2024, 00:00

  • Copyright/Subscription

    Jan 1, 2024, 00:00

  • Characteristics of Prescription Drug Fills Using Pharmacy-Pharmacy Benefit Manager Discount Programs: The “GoodRx” Model

    Jan 1, 2024, 00:00

  • Economic Evaluations of Screening Programs for Chronic Kidney Disease: A Systematic Review

    Jan 1, 2024, 00:00

  • Table of Contents

    Jan 1, 2024, 00:00

  • Best Practices for the Electronic Implementation and Migration of Patient-Reported Outcome Measures

    Jan 1, 2024, 00:00

  • EE652 Assessing the Value of Digital Technologies: A Case Study on Humanoid Robot Assistance in Neurorehabilitation

    Dec 23, 2023, 13:57

  • EE652 Assessing the Value of Digital Technologies: A Case Study on Humanoid Robot Assistance in Neurorehabilitation

    Dec 23, 2023, 13:57

  • Editorial Board

    Dec 1, 2023, 08:12

  • EPH252 A Systematic Review of the Global Burden of Endometriosis

    Dec 1, 2023, 00:00

  • EE413 Economic and Humanistic Burden of Chronic Spontaneous Urticaria: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • EPH80 Survival and Best Recorded Response (BRR) in Patients With Advanced Merkel Cell Carcinoma (MCC): Analysis of a Prospective German MCC Registry Study (MCC TRIM) of the German Dermatologic Cooperative Oncology Group

    Dec 1, 2023, 00:00

  • EE421 Cost-Effectiveness of Empagliflozin in Adult Patients with Chronic Kidney Disease in the Netherlands

    Dec 1, 2023, 00:00

  • EE171 Cost Offset and Budget Impact of Skytrofa for the Treatment of Pediatric Growth Hormone Deficiency: A US Payer’s Perspective

    Dec 1, 2023, 00:00

  • EE566 Systematic Literature Review for Utility Data in Haemophilia

    Dec 1, 2023, 00:00

  • EE486 Municipality Costs Due to COVID-19 Infections in Denmark: A Cost-of-Illness Study

    Dec 1, 2023, 00:00

  • SA34 The Cost-Effectiveness of Community Health Workers in Primary Health Care: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • HTA190 The JCA Is Coming: Will the EU Band Together?

    Dec 1, 2023, 00:00

  • PCR179 The Socio-Economic and Health-Related Quality of Life Impact of Myasthenia Gravis (MG) in Greece

    Dec 1, 2023, 00:00

  • HPR218 Recent Advances in Voluntary European Cross-Border Collaborations in Joint HTA and Drug Pricing/Procurement

    Dec 1, 2023, 00:00

  • EPH230 Systematic Literature Review on the Clinical and Economic Burdens of Antimicrobial Resistance in the Japanese Population

    Dec 1, 2023, 00:00

  • OP4 Scientific Communication Plans in Health Economics and Real-World Evidence

    Dec 1, 2023, 00:00

  • HTA181 How Can Health Technology Assessment Help in Addressing Drug Repurposing Challenges? A Conceptual Framework

    Dec 1, 2023, 00:00

  • PCR229 Achieving Increasingly Stringent Disease Control Criteria Was Associated with Greater Quality of Life Improvements in Patients with Active Psoriatic Arthritis: Results from BE OPTIMAL and BE COMPLETE/BE VITAL up to 1 Year

    Dec 1, 2023, 00:00

  • PCR144 Impact of Oral Corticosteroid Use on Health-Related Quality of Life: Analysis of EQ-5D Data from Navigator

    Dec 1, 2023, 00:00

  • HSD2 Using Automated Data Extraction Methods to Understand the Evolution of Insulin Prescribing in the UK between 2021 and 2022

    Dec 1, 2023, 00:00

  • EE184 Lessons Learned from Model-Based Economic Evaluations of COVID-19 Treatments Under Pandemic Circumstances: Results from a Systematic Review

    Dec 1, 2023, 00:00

  • MSR61 Existing Automated Tools to Assist Evidence Generation and Better Qualification of Registries and Real-World Data: A Systematic Review From the More-EUROPA Project

    Dec 1, 2023, 00:00

  • HTA12 Focus on Two Years of Economic Opinions on Solid Cancers: What Are the Specific Features?

    Dec 1, 2023, 00:00

  • CO113 Impact of Clinical Pharmacist-Led Intervention on Somatic Cell Therapy Medicinal Product Circuit in Portugal

    Dec 1, 2023, 00:00

  • EE605 Methodological Acceptability of the Economic Analyses Assessed by the HAS in 2022

    Dec 1, 2023, 00:00

  • RWD6 Costs of Dose Escalation Among Patients with Inflammatory Bowel Disease Treated with Vedolizumab and Ustekinumab in Portugal

    Dec 1, 2023, 00:00

  • MT52 Economic and Organizational Advantages of Mrgfus for the Treatment of Essential Tremor in Italy

    Dec 1, 2023, 00:00

  • PCR212 A Novel Approach to Capturing Real-World Reasons Behind Use and Satisfaction of NVX-CoV2373 Booster Use Among German Adults: Direct-to-Patient Enrollment

    Dec 1, 2023, 00:00

  • HPR133 Analysis of Information Content on the Web Services About Antihypertensive Medicines in Ukraine

    Dec 1, 2023, 00:00

  • HTA209 A Review of the Differences Between the New EMA-EUnetHTA Joint Scientific Consultation Versus the Previous Ema-HTA Parallel Scientific Consultation

    Dec 1, 2023, 00:00

  • HTA288 How Wide Ranging Is the Implementation of HTA and Cost-Effectiveness Assessment (CEA) in Major Healthcare Markets

    Dec 1, 2023, 00:00

  • MSR82 Combating Sample Scarcity: A Novel Bayesian Approach to Pediatric Basket Trials

    Dec 1, 2023, 00:00

  • EE551 Study of Costs of Hereditary Angioedema in Routine Clinical Practi Economic Impact of the Disease Burden in Spain

    Dec 1, 2023, 00:00

  • MT60 Digital Health Applications (DIGA) in Germany—An Observation of Clinical Evidence Submissions

    Dec 1, 2023, 00:00

  • HPR173 Supply-Side Stakeholders’ Opinions and Perspectives on the Development of Medical Tourism in the Region of Thessaly, Greece

    Dec 1, 2023, 00:00

  • EE256 Economic Burden of Geographic Atrophy: A Systematic Review and Meta-Analysis

    Dec 1, 2023, 00:00

  • EE224 Out-of-Pocket Health Expenditures of Leukemia and Lymphoma Patients in Portugal

    Dec 1, 2023, 00:00

  • HTA160 Development of a Web Application for Self-Assessment and Monitoring of Colorectal Surgery Outcome Indicators in the ESCA Study

    Dec 1, 2023, 00:00

  • EE225 Exploring the Value of Country-Specific Cost-Effectiveness Models in Early Stages of Drug Development

    Dec 1, 2023, 00:00

  • EE193 Evaluating Clinical Benefits of Vertebral Body Stenting in Treating Osteoporotic Vertebral Compression Fracture: A Physician Survey

    Dec 1, 2023, 00:00

  • Projecting the Economic Impact of Compensating Living Kidney Donors in the United States: Cost-Benefit Analysis Demonstrates Substantial Patient and Societal Gains

    Dec 1, 2023, 00:00

  • EE169 Novel Post-Processing Methods for Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Heat Map and Density-Based Clustering

    Dec 1, 2023, 00:00

  • HTA122 How Has NICE's Severity Modifier Been Implemented?

    Dec 1, 2023, 00:00

  • EE665 Evaluation of Resource Use and Costs of Pertuzumab and Trastuzumab Formulations in HER2- Positive Breast Cancer

    Dec 1, 2023, 00:00

  • OP11 What Are the Critical Success Factors for a Biotech’s First Commercialization in Europe to Ensure the Right Decisions Are Made for Their Company, Customers, and Future Patients?

    Dec 1, 2023, 00:00

  • RWD84 Building Federated Data Networks With Common Data Models to Generate Insights Through Real-World Evidence Observational Studies in Oncology

    Dec 1, 2023, 00:00

  • HSD114 Treatment Patterns and Adverse Events (AEs) in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in France, Italy, and the United Kingdom (UK)

    Dec 1, 2023, 00:00

  • EE229 Cost-Effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel in 3L+ Relapsed/Refractory Large B-Cell Lymphoma in the United States Utilizing Real-World Evidence of Chimeric Antigen Receptor T-Cell Therapies

    Dec 1, 2023, 00:00

  • EE750 Budget Impact Analysis (BIA) of Increased COVID-19 Booster Vaccinations in Austria

    Dec 1, 2023, 00:00

  • EE729 Early Intervention With Biosimilars Compared With Leflunomide in Established Rheumatoid Arthritis: A Cost-Effectiveness Analysis in Hong Kong

    Dec 1, 2023, 00:00

  • HPR182 Oncology Combination Market Access Conundrum in Europe

    Dec 1, 2023, 00:00

  • EPH233 Estimation of the Epidemiological and Economic Burden of RSV and Influenza Infection in the Hospital Setting Among Adults 65 Years and Older in France

    Dec 1, 2023, 00:00

  • EE672 Cost-Effectiveness Analysis of Pembrolizumab for the Adjuvant Treatment of Patients With Renal Cell Carcinoma Who Have Undergone Nephrectomy in Greece

    Dec 1, 2023, 00:00

  • EE180 Comparing the Environmental Costs of Differentiated Service Delivery of Antiretroviral Therapy for People Living with HIV in Rural South Africa

    Dec 1, 2023, 00:00

  • EE139 The Need for Economic Systems Modelling to Assess the True Value of Healthcare Innovations: An Application to Influenza Vaccinations

    Dec 1, 2023, 00:00

  • EE503 Impact of Managing Multiple Sclerosis Patients in a Private Health Insurance Company in Brazil

    Dec 1, 2023, 00:00

  • EPH60 Predictive Value of Gensini Score in Severe Coronary Lesions in Algerian Patients Undergoing Coronary Angiography

    Dec 1, 2023, 00:00

  • EPH50 Impact of Dispensed Medication on Mean Age of Death: A Brazilian Public Health System Study

    Dec 1, 2023, 00:00

  • CO54 Recurrence-Free Survival (RFS) as a Surrogate Endpoint (SE) for Overall Survival (OS) in Resected Stage II/III Melanoma: A Correlation Meta-Analysis of Randomized Controlled Trials (RCTs)

    Dec 1, 2023, 00:00

  • EE208 A Total Cost of Care Analysis of Immune-Oncology (IO) Treatments for Unresectable Hepatocellular Carcinoma (uHCC): A Canadian Payer Perspective

    Dec 1, 2023, 00:00

  • HTA236 A Systematic Review of Clinical Efficacy and Safety Data in Penta-Refractory Multiple Myeloma: Findings Indicate the Challenges for HTA Submission

    Dec 1, 2023, 00:00

  • CO112 Clinical Characteristics and Quality of Life of Thai Moderate to Severe Psoriasis Patients Before Initiating Secukinumab: An Interim Analysis from Prompt Study

    Dec 1, 2023, 00:00

  • EE542 Assessment of the Cost-Effectiveness of Risk Factor Guided Prophylaxis with Palivizumab for the Prevention of Severe Respiratory Syncytial Virus Infection in Colombian Infants Born at 32–35 Weeks’ Gestational Age

    Dec 1, 2023, 00:00

  • HTA43 Exploring the Link Between Institutional Country-Level Differences and Consideration of Additional Value Elements in HTAs: Results From a Pragmatic Review

    Dec 1, 2023, 00:00

  • EPH41 Cardiovascular and Renal Replacement Risks in Patients with Sub-Optimally Treated Anemia of Non-Dialysis-Dependent Chronic Kidney Disease

    Dec 1, 2023, 00:00

  • EPH169 Examination of the Quality of Life of Patients Underwent Ischemic Stroke and Treated With Intravenous Thrombolytic and Mechanical Thrombectomy Recanalization Intervention

    Dec 1, 2023, 00:00

  • MT69 Early Health Economic Modelling to Support the Development of Lifechamps Digital Platform for Older Cancer Survivors

    Dec 1, 2023, 00:00

  • MT20 Assessing the Economic Impact of Standardization of Operating Room Workflows Through a Digital Solution

    Dec 1, 2023, 00:00

  • P56 Trends in Prescription Drug Use Among Adults With Diabetes in the United States From 1999-2018

    Dec 1, 2023, 00:00

  • EE276 Cost-Effectiveness Analysis of Dupilumab for the Treatment of Prurigo Nodularis in Adult Patients in Italy

    Dec 1, 2023, 00:00

  • HTA117 A Comparison of Health Technology Appraisal (HTA) Timelines and Requirements for Orphan Technologies in 10 European Countries

    Dec 1, 2023, 00:00

  • EE537 How Good Are Cost-Effectiveness Model Predictions When Compared to Longer Follow-up Data? An Example of Nivolumab Studies in the First-Line Gastro-Oesophageal Setting

    Dec 1, 2023, 00:00

  • PCR223 Characterizing Spillover Effects and Carer Burden in X-Linked Hypophosphatemia

    Dec 1, 2023, 00:00

  • SA64 Systematic Literature Review of Measurement and Valuation Methods for Societal Costs: A Focus on Cost-Effectiveness Analyses of Three Types of Disease Potentially Associated with High Spillover Effects

    Dec 1, 2023, 00:00

  • HSD47 Value for Money of Multidisciplinary Programs for Integrated Care in Dialysis: Being Actively Involved and No Merely Listed Matters

    Dec 1, 2023, 00:00

  • P54 Patient-Reported Health Economic Outcomes for Low-Value Medications in Patients Living with Dementia

    Dec 1, 2023, 00:00

  • HPR128 Addressing Bias in Health Applications: A Path Towards Health Equity

    Dec 1, 2023, 00:00

  • EE350 Budget Impact of Memantine for Alzheimer's Patient in the United States

    Dec 1, 2023, 00:00

  • PCR246 Measuring Treatment Preferences for Patients with Pulmonary Arterial Hypertension (PAH); A Discrete Choice Analysis to Identify Scale Heterogeneity

    Dec 1, 2023, 00:00

  • P12 Screen-Detected Breast Cancers Have Improved 5-Year Disease Free Interval Compared to Interval and Non-Screen-Related Breast Cancer, Taking Lead Time into Account

    Dec 1, 2023, 00:00

  • SA31 Systematic Versus Rapid Reviews: The Impact of Different Methodologies on the Reviews’ Conclusions

    Dec 1, 2023, 00:00

  • HSD90 Beyond the Hospital Walls: Hospital at Home Programs for Cancer Patients Worldwide and the Road to Implementation in Greece

    Dec 1, 2023, 00:00

  • HTA247 Focus on Two Years of Economic Opinions on Orphan Drug: What Are the Specific Features?

    Dec 1, 2023, 00:00

  • EE351 Using Social Return on Investment to Capture the Broader Impact of Medicines: Advanced Parkinson's Disease Example

    Dec 1, 2023, 00:00

  • HSD132 Analysis of Factors Affecting Medication Adherence in Patients with Hypertension in South Korea

    Dec 1, 2023, 00:00

  • MT35 The Impact of Patient Engagement with a Digital Diabetes Solution on All-Cause Healthcare Resource Utilization Rates and Charges

    Dec 1, 2023, 00:00

  • HSD111 Real-World Treatment Patterns of Ankylosing Spondylitis

    Dec 1, 2023, 00:00

  • EE405 Cost-Effectiveness of Single-Inhaler Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium vs Other Open or Single-Inhaler Triple Therapies in Adult Patients with Uncontrolled Asthma in England

    Dec 1, 2023, 00:00

  • SA56 Treatment Patterns of Advanced Egfr-Positive Non-Small Cell Lung Cancer (NSCLC) in Latin America

    Dec 1, 2023, 00:00

  • PCR130 Factors Associated With Adjuvant Treatment Options in Resected Stage III Melanoma, From a Patient and Physician Perspective: Preference Assessment Using the Discrete Choice Experiment Method (Pamela Study)

    Dec 1, 2023, 00:00

  • HTA295 Insights From Economic Evaluations in Emerging Infection Diseases in Fran Focus on COVID-19

    Dec 1, 2023, 00:00

  • PCR245 Stakeholder Engagement and Expert Consultation on the EuroQol Toddler and Infant Populations (EQ-TIPS) Measure of Health-Related Quality of Life (HRQoL)

    Dec 1, 2023, 00:00

  • HTA86 Factors Affecting Time to Reimbursement of Novel Anticancer Drugs in Ireland

    Dec 1, 2023, 00:00

  • EPH155 Burden of Clinical Syndromes Associated with Pneumococcal Disease in Peru: A 2019 Perspective

    Dec 1, 2023, 00:00

  • PCR235 Drivers of Treatment Preferences in High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) Patients: Qualitative Interviews to Inform a Patient-Preference Study

    Dec 1, 2023, 00:00

  • EE404 The Economic Burden That Respiratory Syncytial Virus (RSV) Imposes on Irish Hospitals

    Dec 1, 2023, 00:00

  • HPR74 Analysis of the Guangdong-Hong Kong-Macau Greater Bay Area Urgent-Use Medicine Scheme—An Opportunity for Early Access in Mainland China

    Dec 1, 2023, 00:00

  • EE481 Cost-Effectiveness Analysis of Upadacitinib in Patients with Moderately to Severely Active Ulcerative Colitis in Greece

    Dec 1, 2023, 00:00

  • CO137 Health Outcomes of ALK-Inhibitors in Non-Small Cell Lung Cancer in Real Clinical Practice

    Dec 1, 2023, 00:00

  • CO22 Healthcare Resource Utilization (HCRU), Effectiveness and Safety of Trifluridine/Tipiracil in Treatment of Refractory Metastatic Colorectal Cancer in a Portuguese Comprehensive Cancer Center (PCCC)

    Dec 1, 2023, 00:00

  • HPR15 Review and Evaluation of Health Equity Considerations in Health Technology Assessments in Cystic Fibrosis

    Dec 1, 2023, 00:00

  • HSD31 Impact and Management of Comorbidities in People With Obesity: A Multinational Survey

    Dec 1, 2023, 00:00

  • CO59 Matching-Adjusted Indirect Comparison (MAIC) of Nivolumab + Relatlimab (NIVO+RELA) Vs. BRAF/MEK Inhibitors for First-Line Treatment of BRAF-Mutant Advanced/Metastatic Melanoma (AMEL)

    Dec 1, 2023, 00:00

  • EE368 Would Initiating Colorectal Cancer Screening from Age of 45 Be Cost-Effective in Germany? An Individual-Level Simulation Analysis

    Dec 1, 2023, 00:00

  • EPH103 Estimating the Burden of Vaccine-Preventable Respiratory Diseases Without Vaccination Alternatives in Europe: What's Going on in Spain and Germany?

    Dec 1, 2023, 00:00

  • RWD60 APNEE Study: A Challenge to Identify Patients Treated with Dupilumab for Chronic Rhinosinusitis with Nasal Polyps (CRSWNP) in Real-Life Settings in France

    Dec 1, 2023, 00:00

  • RWD93 Quantifying Trends in Price Setting for Traditional and Innovative Advanced Rare Disease Therapies

    Dec 1, 2023, 00:00

  • EPH209 Incidence Rates for an Extensive List of Adverse Events of Special Interest in the Pre-COVID-19 and Active COVID-19 Eras: A Comprehensive Source for Representative Historical Background Rates in the US General Population

    Dec 1, 2023, 00:00

  • EE317 Microsimulation Model in Obesity: A Feasibility Study Using Object-Oriented C++ Code

    Dec 1, 2023, 00:00

  • MSR90 Is the Current Chatgpt Able to Gatherarticles for HEOR Literature Review

    Dec 1, 2023, 00:00

  • Methodological Statistical Research

    Dec 1, 2023, 00:00

  • EE526 Health Benefits and Cost-Effectiveness Analysis of Early Cervical Cancer Diagnosis in Bulgaria

    Dec 1, 2023, 00:00

  • EPH104 Human Papilloma Virus (HPV) Vaccination: Financial Impact and Recommendations

    Dec 1, 2023, 00:00

  • EPH19 Mental Health Disparities for Young Adults with Arrest Histories in the United States

    Dec 1, 2023, 00:00

  • EPH258 Treatment Pattern of Pemphigus Vulgaris in UK : A Retrospective Cohort Study Using Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES)

    Dec 1, 2023, 00:00

  • EE756 Real World Evidence (RWE) Evaluation of Cost Savings through Continuous Vital Sign Monitoring in the Medical-Surgical Ward: A National Health Service (NHS) Experience

    Dec 1, 2023, 00:00

  • EE397 Determinants of Higher Cost and Inpatient Hospitalization Among Patients with AL Amyloidosis

    Dec 1, 2023, 00:00

  • EE439 Public Health Impact of the Pediatric Immunization Program in the Netherlands

    Dec 1, 2023, 00:00

  • HTA299 A Review of NICE Technology Appraisals of Oncology Treatments in the Past 2 Years – Model Approaches, End of Life Status, and Recommendation Decisions

    Dec 1, 2023, 00:00

  • EE174 Evaluating the Budget Impact of the Co-Existence of Oral and Injectable Forms of Semaglutide in the Saudi Public Healthcare System

    Dec 1, 2023, 00:00

  • EE151 Trade-Off between Comparators Comprehensiveness and Methodological Robustness in Cost-Utility Studies Reviewed By Has in France

    Dec 1, 2023, 00:00

  • RWD156 Real-World Progression Patterns in First and Second Lines of Systemic Therapy for Endometrial Cancer

    Dec 1, 2023, 00:00

  • EPH234 Shedding Light into the Dark of Unknown Cost-of-Illness and Burden-of-Disease Associated with RSV across Age Groups in Austria

    Dec 1, 2023, 00:00

  • RWD154 Using Real World Evidence from the UK MS Register to Support Optimal Healthcare Decision Making

    Dec 1, 2023, 00:00

  • EE111 Indirect Cost Burden for Individuals Living with Transfusion-Dependent Beta-Thalassemia in Europe

    Dec 1, 2023, 00:00

  • SA49 Capturing Real-World Evidence Alongside Trial Evidence in HTA-Specified Systematic Literature Review: Optimizing Search Strategies across the Totality of Evidence Required

    Dec 1, 2023, 00:00

  • EE609 Economic Evaluation and Return-on-Investment (ROI) of Fostering Physical Activity Policies (Simulation With Two Different Tools)

    Dec 1, 2023, 00:00

  • HSD77 The Impact of the COVID-19 Pandemic on Patient Flow and Key Performance Indicators (KPIS) of Hippocration General Hospital of Athens

    Dec 1, 2023, 00:00

  • MSR60 Use of External Control Arms (ECAs) in Marketing Applications Submitted to European Medicines Agency (EMA): A Targeted Review

    Dec 1, 2023, 00:00

  • EE648 Systematic Review of the Cost Effectiveness of Newborn Screening for Spinal Muscular Atrophy

    Dec 1, 2023, 00:00

  • The Impact of Cancer Screening Programs on Population Health Outcomes

    Dec 1, 2023, 00:00

  • RWD67 The Health Resource Utilization and Medical Costs of Cataract Surgery in Pediatric Patients: A National Population-Based Study in a Korea

    Dec 1, 2023, 00:00

  • EE520 Hospital Costs in Resected Patients With Early-Stage Non-Small Cell Lung Cancer (NSCLC): A French Real-World Retrospective Study Based on the National Hospitalization Database (PMSI)

    Dec 1, 2023, 00:00

  • HTA18 Challenges of Identifying Health Utility Data for Patients With Penta-Refractory Multiple Myeloma to Inform HTA Reimbursement Discussion for Newer Treatment Options

    Dec 1, 2023, 00:00

  • EE218 Budget Impact and Cost Minimization Analysis of Phesgo ® (Trastuzumab + Pertuzumab SC) for the Treatment of HER2+ Breast Cancer in the Chilean Public Health System

    Dec 1, 2023, 00:00

  • HTA315 Implications for Rare Diseases: NICE Guidance and Outcomes on Implementing Bayesian Borrowing Approaches for External Control Data

    Dec 1, 2023, 00:00

  • PCR247 Is the Symptomatology of Infantile Tay-Sachs and Infantile Sandhoff Disease Identical? Data from an International Registry

    Dec 1, 2023, 00:00

  • PCR52 Use of Patient Reported Outcomes in Key Trials Supporting Marketing Authorisation: 5-Year Analysis of Company Evidence Submitted for National Institute for Health and Care Excellence (NICE) Single Technology Appraisal (STA)

    Dec 1, 2023, 00:00

  • EPH45 Exploring the Pandemic's Impact: An Examination of Adolescent and Adult Vaccination Rates in Different Countries During COVID-19

    Dec 1, 2023, 00:00

  • EE163 Cost Effectiveness of Implantable Cardioverter Defibrillator Therapy Versus Drug Therapy in Patients for Primary Prevention in China

    Dec 1, 2023, 00:00

  • HTA39 A Valuable Perspective on Medical Devices – Assesing the Organizational Impact of Health Technologies in Decision-Making

    Dec 1, 2023, 00:00

  • HTA278 Risky Business: How Does Risk of Study Bias Impact Health Technology Assessment Submissions?

    Dec 1, 2023, 00:00

  • HPR115 Patient Access Network: Multi-Stakeholder Shared Policy Strategies for Medical Device Access

    Dec 1, 2023, 00:00

  • RWD11 Real-World Persistence on Cladribine Tablets of Patients with RMS over 4 Years Based on Claims Data

    Dec 1, 2023, 00:00

  • HTA46 Relationship Between the Directness of the Evidence and Identification of Added Therapeutic Value: An Analysis of HTA Procedures

    Dec 1, 2023, 00:00

  • EPH207 The Adverse Event Profiles of Modafinil in Approved Indications and Off-Label Use for Major Depressive Disorder: A Systematic Review and Meta-Analysis

    Dec 1, 2023, 00:00

  • EE308 Cost-Utility Analysis of Universal Neonatal Screening for Critical Congenital Heart Disease Based on Pulse Oximetry in Spain

    Dec 1, 2023, 00:00

  • EPH274 Health-Related Quality of Life in a Large Cohort of Adult Patients With Sickle Cell Disease in France (The DREPAtient Study)

    Dec 1, 2023, 00:00

  • HPR163 Underinvestment in Pharmaceutical Care and Unmet Pharmaceutical Needs Among Older European Adults

    Dec 1, 2023, 00:00

  • MSR98 Generate Synthetic Data in R for a Hypothetical Alzheimer's Disease Trial

    Dec 1, 2023, 00:00

  • MT26 Implications of the Implementation of the Joint Committee Assessment on Launch Planning for Medical Technologies in Europe

    Dec 1, 2023, 00:00

  • EE685 Screen-and-Treat Cervical Cancer Screening Strategy Using High-Risk HPV Testing: Early Evaluation for Uganda

    Dec 1, 2023, 00:00

  • Economic Evaluation

    Dec 1, 2023, 00:00

  • SA27 Menopause: More Than Just Vasomotor Symptoms

    Dec 1, 2023, 00:00

  • P31 Evidence Supporting Regulatory Withdrawals and Quantifying Their Impact on Public Health

    Dec 1, 2023, 00:00

  • HTA75 Evaluation of the Clinical and Economic Effectiveness of Continuous Glucose Monitoring in Adults With Type 1 Diabetes Mellitus in the Healthcare System of the Republic of Kazakhstan

    Dec 1, 2023, 00:00

  • EE390 Optimizing the Use of Risk Factors to Guide the Cost-Effective Use of Palivizumab Prophylaxis Against Severe Respiratory Syncytial Virus Infection in Korean Infants Born 32–35 Weeks’ Gestational Age

    Dec 1, 2023, 00:00

  • HTA290 Environmental Sustainability in HTA: Are HTA Bodies Applying Environmental Criteria in Their Decision-Making?

    Dec 1, 2023, 00:00

  • PCR207 A Vignette Study to Derive Health-Related Quality of Life Weights for Patients With Steroid Refractory Chronic Graft-Versus-Host Disease Receiving Third Line Therapy in the United Kingdom

    Dec 1, 2023, 00:00

  • EPH63 Obesity Related Complications: Can America Be Europe's Canary in the Coal Mine?

    Dec 1, 2023, 00:00

  • HTA4 The Challenges of Health Economic Modeling for Mental Health, Behavioral, and Neurodevelopmental Conditions

    Dec 1, 2023, 00:00

  • EPH154 Modeled Head-to-Head Comparison of Nirsevimab and Rsvpref Maternal Vaccine in the US

    Dec 1, 2023, 00:00

  • RWD150 A Prescription Pattern of HIV First-Line Tenofovir Alafenamide-Based Single-Tablet Regimens: A Multi-Institutional Study in Taiwan

    Dec 1, 2023, 00:00

  • PT18 Novel Approaches to Unify Multi-State Transition Modelling Methods and Develop a Synthetic English Population to Support Health Economic Evaluation Studies

    Dec 1, 2023, 00:00

  • CO175 OCTOPUS: Ambispective Observational Study Describing Diagnosis and Treatment Patterns in Adults with Metastatic NSCLC with BRAF V600E Mutation in Clinical Practice, to Assess Treatment Effectiveness and Quality of Life (TIP)

    Dec 1, 2023, 00:00

  • EPH21 An Assessment of Validated Algorithms for Identifying Multiple Sclerosis Cases, Subtypes, and Relapses in Real-World Databases: A Systematic Review

    Dec 1, 2023, 00:00

  • RWD132 Impact of Exacerbations on Disease Burden of COPD: A Retrospective Observational Database Cohort Study in Tianjin, China

    Dec 1, 2023, 00:00

  • HTA53 Proportionally Quicker or Easier? International Comparison of NICE’s Proportionate Approach to Technology Appraisals (PATT) With Global Peers

    Dec 1, 2023, 00:00

  • MSR147 Accounting for Study Heterogeneity When Modelling the Multi-State Natural History of Rare Diseases

    Dec 1, 2023, 00:00

  • HSD36 Impact of Non-Medical Factors on Patterns of Treatment in Patients With Cancer: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • PCR204 Impact of Roflumilast Foam 0.3% on Patient-Reported Quality of Life in Seborrheic Dermatitis: An Analysis of Stratum Data for Patients Unresponsive or Intolerant to Topical Corticosteroids

    Dec 1, 2023, 00:00

  • P46 Drivers of Health Technology Assessment Methods and Process Reforms: An International Comparison of Real World Evidence, Patient Involvement and Discounting

    Dec 1, 2023, 00:00

  • HTA313 The Same but Different: Inconsistencies in Key Cost-Effectiveness Assumptions for Curative Therapies across Clinically Similar NICE Appraisals

    Dec 1, 2023, 00:00

  • EE60 An Overview of Systematic Reviews of Economic Evaluations on Cancer Screening: Landscape, Quality, and Recommendations

    Dec 1, 2023, 00:00

  • HTA152 Multidimensional Evaluation of Inebilizumab in Patients With Neuromyelitis Optica Spectrum Disorder

    Dec 1, 2023, 00:00

  • SA36 Safety, Efficacy, Quality of Life, and Treatment Dynamic of Conventional Therapies for Adults and Adolescents Suffering From Eosinophilic Esophagitis, a Type 2 Inflammatory Disease: Qualitative and Quantitative Synthesis

    Dec 1, 2023, 00:00

  • PCR138 An International Study of Patient and Caregiver-Reported Burden and Quality of Life in Wiskott-Aldrich Syndrome

    Dec 1, 2023, 00:00

  • EE107 Estimating EQ-5D Utilities From the Facial Vitiligo Area Scoring Index (F-VASI) in Vitiligo Patients Using a Mapping Algorithm Applied to 2 Pooled Randomized Controlled Trials

    Dec 1, 2023, 00:00

  • EE573 Economic Burden of Chronic Kidney Disease with Type 2 Diabetes in Turkiye

    Dec 1, 2023, 00:00

  • CO142 A Retrospective Study Characterizing Age at Key Clinical Disease Indicators Among Patients With Friedreich Ataxia Using Health Administrative Claims Data in the United States

    Dec 1, 2023, 00:00

  • SA83 {Maicplus}: An R Package to Support Analysis and Reporting of Matching Adjusted Indirect Treatment Comparisons (MAIC) for HTA Dossiers

    Dec 1, 2023, 00:00

  • CO4 Overview of Recent Systematic Literature Reviews on Glucagon-like Peptide-1 Receptor Agonists for Weight Loss in Adults with Obesity

    Dec 1, 2023, 00:00

  • PCR153 Pace CKD: The Impact of Chronic Kidney Disease and Dialysis on Caregivers Financial Status, and Work Productivity: Results from a Multinational Survey

    Dec 1, 2023, 00:00

  • MSR67 Art or Science? Selecting Utility Evidence for Decision-Analytic Models Containing Multiple Health-States

    Dec 1, 2023, 00:00

  • HPR46 Payers’ Perceptions of Current Policy Approaches to Address Antimicrobial Resistance in Europe

    Dec 1, 2023, 00:00

  • EPH44 Temporary Soft Tissue Coverage in Burn Patients - Which Materials Are Used - and By Whom? Analysis of German Billing Data

    Dec 1, 2023, 00:00

  • EE327 Cost-Effectiveness of Teduglutide in Adult and Pediatric Patients with Short Bowel Syndrome in Argentina: A Markov Model Analysis

    Dec 1, 2023, 00:00

  • SA74 A Systematic Literature Review to Assess the Level of Evidence in Facioscapulohumeral Muscular Dystrophy

    Dec 1, 2023, 00:00

  • EE341 Cost-Utility Analysis of a Multi-Center, Parallel Group Randomized Controlled Trial of an Adapted Parenting Intervention (EPICC-ID) to Reduce Challenging Behavior in Pre-Schoolers with Moderate to Severe Intellectual Disability

    Dec 1, 2023, 00:00

  • CO37 Inventory-Facilitated Goal Setting Interview Conducted by Disease Experts Yields a Broader Range of Goal Areas

    Dec 1, 2023, 00:00

  • PCR261 Uncovering Patient-Reported Outcome Differences Between Undiagnosed and Diagnosed Individuals With Moderate to Severe Psoriasis in Europe

    Dec 1, 2023, 00:00

  • HPR65 Pricing and Reimbursement Mechanisms for Advanced Therapeutic Medicinal Products in 20 Countries

    Dec 1, 2023, 00:00

  • EE393 The Cost-Effectiveness of Atidarsagene Autotemcel (Arsa-Cel) for the Treatment of Metachromatic Leukodystrophy (MLD) in the US

    Dec 1, 2023, 00:00

  • PCR16 Uncovering the Influence of Smoking on Health Care Processes for Adult Lung Cancer Patients in Chile: Insights From a Multi-Perspective Qualitative Study

    Dec 1, 2023, 00:00

  • EE687 Cost Analysis of Prostav®: A New Telomere-Based Biomarker for the Early Detection of Prostate Cancer Available in Europe

    Dec 1, 2023, 00:00

  • EPH122 Global Burden of Disease Study on Chikungunya: Estimating Dalys and Cost Burden

    Dec 1, 2023, 00:00

  • HPR152 Evolution of the Use of Medicines in Special Situations and Management Measures for Their Rational Use

    Dec 1, 2023, 00:00

  • HPR207 Moving to Outcomes-Based Agreements in Algeria: Sharing Experiences Between Saudi Arabia and Algeria

    Dec 1, 2023, 00:00

  • EPH167 The Conceptualization of Cardiometabolic Disease Policy Model in the UK

    Dec 1, 2023, 00:00

  • PCR225 The Added Value of the Cognition, Dining, Gastrointestinal Problems, Sleep, and Tiredness Bolt-Ons for the EQ-5D-5L in Patients With Coeliac Disease

    Dec 1, 2023, 00:00

  • EE583 Unraveling Modeling Challenges in the Economic Evaluations of Gene Therapies: A Global Review

    Dec 1, 2023, 00:00

  • HPR9 Value Criteria for Outcomes Based Managed Entry Agreement of CAR-T in Relapsed or Refractory Multiple Myeloma (RRMM) through MCDA

    Dec 1, 2023, 00:00

  • HTA174 Single-Arm Studies in Rare Diseases and Statistical Methods to Mitigate Lack of Comparative Data: What Kind of Assessment Is More Successful for the French HTA Body?

    Dec 1, 2023, 00:00

  • EE79 Cost-Utility Analyses of Glofitamab for the Treatment of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma after Two or More Lines of Systemic Therapy in Italy

    Dec 1, 2023, 00:00

  • HTA259 Exploring Collaboration on HTA Methodology for Medical Technologies in the Dutch ZonMw HTA Methodology 2021-2024 Subsidy Program

    Dec 1, 2023, 00:00

  • HSD130 Development of a Risk-Adjusted in-Hospital Complication Rate (RAICR) Using Machine Learning Methods

    Dec 1, 2023, 00:00

  • MSR130 Current Trends in Quantitative Bias Analysis for Unmeasured Confounders: A Targeted Literature Review

    Dec 1, 2023, 00:00

  • EE465 Sacubitril/Valsartan Vs Enalapril Use in the Outpatient Facilities Setting in Spain

    Dec 1, 2023, 00:00

  • MT12 Comparison of Hospital Case Characteristics of Popliteal Artery Aneurysm Repair with ePTFE Covered Stent Grafts with a Heparin Bioactive Surface and Open Surgical Bypass: Highlights from the 2021 Hospital Dataset in Germany

    Dec 1, 2023, 00:00

  • EE4 Cost-Effectiveness of Andexanet Alfa Versus Prothrombin Complex Concentrate Is Likely for the Treatment of Factor Xa Inhibitor–Related Major Bleeds in the Netherlands

    Dec 1, 2023, 00:00

  • HTA14 Expanding the HTA Cost-Effectiveness Analyses for CheckMate 9LA: Nivolumab Plus Ipilimumab Plus Chemotherapy As First-Line Strategy for Non-Small Cell Lung Cancer

    Dec 1, 2023, 00:00

  • EE546 Development of a Drug Price Index for Approved Cystic Fibrosis Treatments

    Dec 1, 2023, 00:00

  • PCR119 The CaOa-QoL-TS: Development and Validation of an Owner-Completed Health-Related Quality of Life and Treatment Satisfaction Measure in Canine Osteoarthritis

    Dec 1, 2023, 00:00

  • RWD9 Identifying Predictors of Response Following Discontinuation of JAKi Therapy in Patients with Rheumatoid Arthritis

    Dec 1, 2023, 00:00

  • EE445 Economic Evaluation of Alternative Measles-Mumps-Rubella Childhood Vaccination Schedules in Denmark

    Dec 1, 2023, 00:00

  • EE553 An Exploratory Study Assessing the Utility Impact in Second Informal Carers of Patients With Epidermolysis Bullosa

    Dec 1, 2023, 00:00

  • HPR204 Reimbursement Status of Centrally Authorized Drugs in Spain per Therapeutic Area and Orphan Designation

    Dec 1, 2023, 00:00

  • EPH198 Annual Health Insurence Treatment Cost of Polycystic Ovary Sindrome Based on Routinely Collected Financing Data Between 2010-2019

    Dec 1, 2023, 00:00

  • HTA184 Review of HTA Evaluation for Gene Therapies and Their Future Implications in Europe

    Dec 1, 2023, 00:00

  • MT53 Remote Symptom Monitoring for Lung Cancer Patients: Lessons Learned from the Lung Aid Study

    Dec 1, 2023, 00:00

  • CO83 Disease Burden of Moderate to Severe Ulcerative Colitis in Chinese Patients Under Current Care: A Model Simulation Study

    Dec 1, 2023, 00:00

  • EE521 Economic Evaluation of Trastuzumab Deruxtecan for HER2+ Advanced Gastric Cancer Patients

    Dec 1, 2023, 00:00

  • Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0

    Dec 1, 2023, 00:00

  • HTA322 Modelling Antifibrotic Therapies for Idiopathic Pulmonary Fibrosis and Progressive Fibrosing Interstitial Lung Disease: Learnings from NICE Submissions from the Past Decade

    Dec 1, 2023, 00:00

  • MSR65 The Impact of Censoring Assumptions in the Generation of Individual Patient Data from Kaplan-Meier Estimates

    Dec 1, 2023, 00:00

  • HPR45 Trends in Semaglutide Prescribing and Dispensing – a Nationwide Register-Based Study

    Dec 1, 2023, 00:00

  • HTA73 Health Technology Assessment (HTA) Timelines Analysis in the Post-COVID Era: Comparison of HTA Process Duration in the First Half (H1) of 2023 to H1 2022

    Dec 1, 2023, 00:00

  • EE711 Cost-Effectiveness of Umeclidinium/Vilanterol (UMEC/VI) Versus Tiotropium/Olodaterol (TIO/OLO) in Patients With COPD: United Kingdom Payer Perspective

    Dec 1, 2023, 00:00

  • EPH148 Disease Burden of Sickle Cell Disease in Saudi Arabia

    Dec 1, 2023, 00:00

  • PCR253 The Burden of Persistent Cough in Idiopathic Pulmonary Fibrosis (IPF) and Other Interstitial Lung Diseases (ILD): A Systematic Evidence Synthesis

    Dec 1, 2023, 00:00

  • HSD87 Physician Reported Reasons for Cidp Treatment Choice across 5 European Countries: Results from a Real-World Survey

    Dec 1, 2023, 00:00

  • EPH237 Incidence and Risk Factors for Psychiatric Disorders Across Different Health Insurance Systems in Japan

    Dec 1, 2023, 00:00

  • EE733 Distributional Cost-Effectiveness Analysis: A Case Study on Its Potential Prospects in HTA

    Dec 1, 2023, 00:00

  • EE396 Economic Evaluation of PD-1 Blockers in Merkel Cell Carcinoma: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • EE448 Exploring Non-Patient Utilities Using Time Trade-Off Exercises in the UK General Population

    Dec 1, 2023, 00:00

  • EE354 Value for Money: Evaluating the Economic Benefit of a Hypothetical Disease Modifying Therapy for Alzheimer's Disease From Canadian Payer and Societal Perspectives

    Dec 1, 2023, 00:00

  • EPH212 The Acceptability of Human Papillomavirus Vaccination in the United Kingdom: A Review of the Literature on Barriers and Facilitators to Vaccination

    Dec 1, 2023, 00:00

  • CO73 Overview of COA Measures in SLE Clinical Trials and Label Claims

    Dec 1, 2023, 00:00

  • EE280 The Lean Assessment Process (LAP) Methodology: An Iterative and Multi-Disciplinary Method for Identifying Clinical Needs, Assessing Technology Acceptance, a Precursor for Early Economic Evaluation and Adoption Strategies

    Dec 1, 2023, 00:00

  • EE565 Healthcare Consumption and Costs of Hemophilia B in France

    Dec 1, 2023, 00:00

  • EE415 Effect of Vitamin C Use on Cost of Common Cold in Turkiye

    Dec 1, 2023, 00:00

  • EE114 Reductions in Travel Time and CO2 Emissions Arising From Patient Transportation to Hospitals in Ireland for Treatment With Intravenous Iron: An Analysis Comparing Ferric Derisomaltose With Ferric Carboxymaltose

    Dec 1, 2023, 00:00

  • EPH14 Burden of Respiratory Syncytial Virus Infection in Germany: A Systematic Review

    Dec 1, 2023, 00:00

  • EPH16 Exploring the Effects of the COVID-19 Pandemic on Pneumococcal Disease in Fran A Comprehensive Analysis of Public Health Impact and Economic Burden

    Dec 1, 2023, 00:00

  • CO20 Use of Inpatient Systemic Chemotherapy and/or Radiotherapy and Related Predictive Factors for Metastatic Urothelial Cancer (mUC): Findings from a Retrospective Observational Study in a Clinical Practice Setting in Italy

    Dec 1, 2023, 00:00

  • OP15 Analysis of the Multidisciplinary Approach for the Management of Patients Affected by Waldenstrom's Macroglobulinemia, Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia in Italy

    Dec 1, 2023, 00:00

  • EE490 Analysis of Access and Avalibility of Low Molecular Heparins for the Treatment of COVID-19 during Wartime in Ukraine

    Dec 1, 2023, 00:00

  • EE645 How Wrong Can It Be? The Impact of Using Inappropriate Adult-Specific Value Set for EQ-5D-Y in Cost-Effectiveness Estimates

    Dec 1, 2023, 00:00

  • HSD57 Adherence Teleassistance-Based Program Impact in a Real-Life Diabetes Colombian Patient Cohort

    Dec 1, 2023, 00:00

  • EE730 Modelling Considerations for Evaluating the Cost-Effectiveness of Biologics in Eosinophilic-Associated Diseases

    Dec 1, 2023, 00:00

  • HSD80 Employees Satisfaction Working at Arta General Hospital of Greece

    Dec 1, 2023, 00:00

  • PCR74 Patient-Centricity in Haemato-Oncology and Oncology Clinical Trials – A Systematic Literature Review on FDA-Approved Treatments From January 2020 to June 2023

    Dec 1, 2023, 00:00

  • RWD72 Status of the Art on Global Clinical Trials of Patient-Managed Digital Medical Devices (pDMD): 2023 Original Data Analysis From Multiple Sources

    Dec 1, 2023, 00:00

  • EE717 Healthcare Resource Utilization Among Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in France

    Dec 1, 2023, 00:00

  • EPH232 The Disease Burden and Healthcare Resource Utilization of Gram-Negative Multi-Drug Resistant Bacteria

    Dec 1, 2023, 00:00

  • EE456 Cost-Effectiveness of the Development Assistance for Health in Sub-Saharan Africa for HIV, Malaria and Tuberculosis (1995-2018)

    Dec 1, 2023, 00:00

  • EE69 Cost-Utility Analysis of Lorlatinib for First-Line Treatment for ALK Positive Advanced Non-Small Cell Lung Cancer in China

    Dec 1, 2023, 00:00

  • EE681 Economic Impact of Fixed-Treatment Duration for Chronic Lymphocytic Leukemia: Budget-Impact Analysis of Venetoclax Plus Obinutuzumab for First Line Treatment of Unfit Patients in France

    Dec 1, 2023, 00:00

  • EE629 The Obesity Burden and Impact of Weight Loss on Saudi Public Payers Using Value of Weight Loss Simulation Model

    Dec 1, 2023, 00:00

  • EE760 Using Discrete Choice Experiment to Elicit Treatment Preferences for Acute Allergic Reactions in Sweden: The Case of Patients with Swallowing Problems

    Dec 1, 2023, 00:00

  • CO89 Efficacy of Anti-Alzheimer’S (AD) Drugs in Cognitive Improvement: A Network Meta-Analysis (NMA) of Randomized Controlled Trials (RCTS)

    Dec 1, 2023, 00:00

  • HTA186 Accelerating Access to Medical Technologies: An Overview of the NICE Early Value Assessment Pilot Project in the UK

    Dec 1, 2023, 00:00

  • HSD22 Vaccine Preparation Time, Cost, and Preference Comparison Between Pre-Filled Syringe Formulations and Vaccines That Require Reconstitution: A Targeted Literature Review

    Dec 1, 2023, 00:00

  • CO186 Characteristics of Psoriasis Patients According to Their Level of Severity Based on a Real-World Ambulatory Medical Database in Fran Preliminary Results

    Dec 1, 2023, 00:00

  • Medication Use and Its Consequences

    Dec 1, 2023, 00:00

  • HPR212 The Use of Managed Entry Agreements (MEAs) for Accessing Innovative Health Technologies

    Dec 1, 2023, 00:00

  • CO68 Gastrointestinal Manifestations and Incontinence Products in the Real World Among Patients with Rett Syndrome in the United States

    Dec 1, 2023, 00:00

  • PT19 Analysis of the Access to Medicines for Rare Diseases in Countries from the Balkan Peninsula: A Comparative Analysis

    Dec 1, 2023, 00:00

  • EPH106 Intercultural Approach and Knowledge of Migrant Health Policy in Healthcare Teams and Migrants in Chile

    Dec 1, 2023, 00:00

  • EE516 Cost-Utility Analysis (CUA) in Chronic Lymphocytic Leukemia (CLL): Is COVID-19’s Impact on National Life Tables Important to Consider?

    Dec 1, 2023, 00:00

  • EE538 Hospital Budget Impact of a Lung Suite Navigation Platform to Diagnose and Treat Lung Cancer Patients

    Dec 1, 2023, 00:00

  • MT64 The Role of Digital Health Technologies in Out-of-Hospital Management of Mental Health Disorders in the UK

    Dec 1, 2023, 00:00

  • EE178 A Targeted Literature Review of Cost-Utility Analyses for Ulcerative Colitis/Crohn’s Disease Treatment

    Dec 1, 2023, 00:00

  • CO86 Comparing Factors Associated With First and Recurrent Psychiatric Hospitalizations in Adult Patients With Major Depressive Disorder Using Cox Proportional Hazard Model and Extensions

    Dec 1, 2023, 00:00

  • CO62 Network Meta-Analysis (NMA) of Immuno-Oncology (IO) Treatments for First-Line (1L) Advanced or Metastatic Melanoma

    Dec 1, 2023, 00:00

  • EE70 Real-World Comparison of Healthcare Resource Utilization and Costs Between Patients with Chronic Lymphocytic Leukemia Treated with First-Line Ibrutinib or Acalabrutinib

    Dec 1, 2023, 00:00

  • EPH61 Epidemiology of Tumor-Related Hypothalamic Obesity in Germany—A Representative Claims Data Analysis

    Dec 1, 2023, 00:00

  • EE684 Economic Evaluation of Focal Therapy Used in the Treatment of Prostate Cancer: A Systematic Review

    Dec 1, 2023, 00:00

  • EE93 Real-World Cost-Effectiveness of Asfotase Alfa for Treatment of Patients with HPP in England

    Dec 1, 2023, 00:00

  • EE250 Economic Evaluation and Budget Impact of ERTs in Patients with Pompe Disease – a Systematic Literature Review

    Dec 1, 2023, 00:00

  • EPH184 The Relevance of Insomnia in Relation to Other High-Impact Pathologies. a Systematic Literature Review

    Dec 1, 2023, 00:00

  • HPR28 Health Technology Assessment of New Drugs in Spain: Understanding the Evaluators’ Evidence Needs

    Dec 1, 2023, 00:00

  • PCR108 Pilot Testing the Hungarian Version of Online Elicitation of Personal Utility Functions Tool for Valuing EQ-5D-5L Health States

    Dec 1, 2023, 00:00

  • CO134 Estimating the Direct and Indirect Resource Burden of Treatment Management with Current Standard of Care or Elacestrant for ER+, HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer Patients: A Population-Level Provider Model

    Dec 1, 2023, 00:00

  • EE418 Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Treating Iron Deficiency Anemia in Norwegian Patients With Inflammatory Bowel Disease

    Dec 1, 2023, 00:00

  • HPR52 Working Market for Patients Living With Advanced Breast Cancer in Portugal: Call for Action

    Dec 1, 2023, 00:00

  • EE11 Budget Impact of Patient Blood Management in the Cardiovascular Surgery Department of a Turkish Private Hospital

    Dec 1, 2023, 00:00

  • PCR70 Factors Associated with Taking Preventive Migraine Medicines: Results from Overcome (EU) Study

    Dec 1, 2023, 00:00

  • EPH90 The Increasing Incidence of Respiratory Syncytial Virus (RSV) in Ireland

    Dec 1, 2023, 00:00

  • EE594 Comparison of the Clinical and Economic Impact of Two COVID-19 Vaccines in Immunocompromised Patients in France

    Dec 1, 2023, 00:00

  • HTA262 Cost-Utility Analysis of Influenza Vaccination with a High Dose Quadrivalent Vaccine for the Brazilian Elderly Population in the Private Healthcare Sector

    Dec 1, 2023, 00:00

  • EE241 Budget Impact of Making Emicizumab Available at the Community Pharmacy in Addition to the Hospital Pharmacy

    Dec 1, 2023, 00:00

  • HTA246 A QALY Is Not a QALY When It Comes to Health Technology Appraisals of Pediatric Rare Diseases

    Dec 1, 2023, 00:00

  • EE36 Economic Burden of Adults Hospitalized with Respiratory Syncytial Virus Infection in Spain, 2016–2019

    Dec 1, 2023, 00:00

  • CO84 Characterization of Long-COVID Phenotypes and Associated Clinical Phenotypes in Administrative Claims Data

    Dec 1, 2023, 00:00

  • MSR36 Model Framework to Derive Prevalence Estimates of Hepatitis Delta Based on Migration Patterns

    Dec 1, 2023, 00:00

  • EPH136 Treatment Patterns and Epidemiological Characteristics in Adult Patients With III-IVB HNSCC From a Reference Center in Mexico

    Dec 1, 2023, 00:00

  • RWD170 Investigating the Association between Pain Burden and Multimorbidity Among United States Adults with Pain

    Dec 1, 2023, 00:00

  • CO53 A Review of Treatment Effect Modifiers and/or Prognostic Factors Included in Unanchored Indirect Treatment Comparisons (ITCs) Involving Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

    Dec 1, 2023, 00:00

  • EE600 Prediction of Price Dynamics of Medicine in the Netherlands

    Dec 1, 2023, 00:00

  • EPH105 Effects of Abortion Debate on Fertility Intentions of Women of Childbearing Age

    Dec 1, 2023, 00:00

  • EE138 Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Singaporean Adults Aged ≥18 Years

    Dec 1, 2023, 00:00

  • EE632 Identification of Health State Utility Values for Health Economic Models: Empirical Testing of Alternative Search Methods

    Dec 1, 2023, 00:00

  • HTA187 Advancing a Collaborative Value Assessment Framework for Next-Generation Sequencing/Comprehensive Genomic Profiling in Europe: Building on and Enhancing an Existing Framework – A Multi-Stakeholder Web-Delphi Approach

    Dec 1, 2023, 00:00

  • EE559 The Burden of Disease of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Honduras, El Salvador, Dominican Republic

    Dec 1, 2023, 00:00

  • EE500 An Overview of Systematic Literature Review of Economic Evaluation of Treatment on Patients With Alzheimer's Disease and Related Dementia

    Dec 1, 2023, 00:00

  • Real-World Data Information Systems

    Dec 1, 2023, 00:00

  • RWD175 A Data Quality Framework to Assess Healthcare Data in Saudi Arabia: An Automated Approach

    Dec 1, 2023, 00:00

  • CO183 Simulated Treatment Comparison and Matching-Adjusted Indirect Comparison of the Efficacy of Eplontersen and Vutrisiran for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

    Dec 1, 2023, 00:00

  • CO51 Safety Profile of Approved Alzheimer's Medication By USFDA

    Dec 1, 2023, 00:00

  • MSR34 Feasibility of Using Finnish Real-World Data to Build an External Control Arm for the Factor Xia Inhibitor Asundexian Pacific-AF Trial

    Dec 1, 2023, 00:00

  • EE316 The Cost-Saving of the Introduction of Dapagliflozin in Algeria After Primary Failure of Oral Anti-Diabetics in Patients With Types 2 Diabetes (T2DM)

    Dec 1, 2023, 00:00

  • EE314 Ferric Carboxymaltose in the Treatment of Iron Deficiency in Patients With Heart Failure From the Perspective of Private Health Care System: Cost-Effectiveness Analysis and Budget Impact in Brazil

    Dec 1, 2023, 00:00

  • PCR201 Estimating the Respiratory Syncytial Virus (RSV) Health Utility Values for Older Adults and Their Caregivers in the Japanese Population: A Time Trade-Off (TTO) Study

    Dec 1, 2023, 00:00

  • HSD39 Treatment Pathway and Unmet Needs of Mantle Cell Lymphoma Patients: An Exploratory Study from Portugal

    Dec 1, 2023, 00:00
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10 (current)
  • »